| |
|
|
|
Keystone Symposia, Lake Louise, Alberta, Canada
February 1 - 6, 2007
Therapeutic antibodies have become important components of standard care in some areas of clinical practice, but lag behind in others. What can be learned from prior successes and failures of antibody drug development? Interdisciplinary discussions spanning immunobiology, protein engineering, bioprocess development, pharmacokinetics, and clinical medicine for neurological disease, infectious diseases, immunological diseases, and cancer should help identify crosscutting themes and general approaches.
|
|
|
|
|
|
|
|
Organized by:
|
|
Jochen G. Salfeld and Karl Dane Wittrup |
|
|
Invited Speakers:
|
|
- George Avgerinos, Abbott Bioresearch Center
- Richard Begent, Royal Free and University College Medical School
- Dennis Burton, The Scripps Research Institute
- Michael Carroll, Harvard Medical School
- Abbie Celniker, Millennium Pharmaceuticals
- Michael Diamond, Washington University School of Medicine
- Birgitta Heyman, Uppsala University
- Roy Jefferis, University of Birmingham
- Antonio Lanzavecchia, Institute for Research in Biomedicine
- Steven Larson, Memorial Sloan-Kettering Cancer Center
- James Marks, University of California, San Francisco
- Eliezer Masliah, University of California, San Diego
- Dario Neri, Institut f. Pharmazeut, Wissenschaften
- Michael Pfreundschuh, University of Saarland
- Andreas Plückthun, University of Zürich
- Jeffrey Ravetch, Rockefeller University
- Jan Schnitzer, Sidney Kimmel Cancer Center
- Andrew Scott, Ludwig Institute for Cancer Research
- Steven Shire, Genentech, Inc.
- Eric Shusta, University of Wisconsin, Madison
- Paul-Peter Tak, University of Amsterdam
- Ian Tomlinson, Domantis Limited
- E. Ward, University of Texas Southwestern Medical Center
- Louis Weiner, Fox Chase Cancer Center
- Cornelia Weyand, Emory University School of Medicine
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
Oct. 2, 2006
|
|
|
|
|
|
|
|
Registration:
|
|
Please see website
|
|
|
E-mail:
|
|
info@keystonesymposia.org
|
|
|
|
|
|
|
|
|